The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

Key Points Revenue (GAAP) for Q2 2025 exceeded estimates by 47.1%, reaching $0.3 million due to continued NIH grant income. Net loss (GAAP) for Q2 2025 widened to $21.5 million, driven by a 79% surge ...

Novel Mechanism Demonstrates Clinically Meaningful Prevention of Weight Rebound and Metabolic Benefits After Stopping GLP-1 Therapy ...

MediPharm Labs states it is positioned for potential U.S. cannabis rescheduling, having completed FDA site registration and ...

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("'2510") anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presen ...

Ozempic a brand name for semaglutide works by mimicking a natural hormone that helps your body regulate blood sugar reduce ...

Q2 2025 Earnings Call Transcript August 12, 2025 TriSalus Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good afternoon, and ...

August 12, 2025. Vicarious Surgical Inc. beats earnings expectations. Reported EPS is $-2.23, expectations wer ...

HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...

Startup founders are thankful for the state-run grant programs, one of the few available non-dilutive funding options available to them right now.